PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Stock Holdings Increased by Chicago Capital LLC

Chicago Capital LLC grew its position in PROCEPT BioRobotics Corporation (NASDAQ:PRCT - Free Report) by 11.3% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 422,373 shares of the company's stock after purchasing an additional 42,791 shares during the period. Chicago Capital LLC owned approximately 0.77% of PROCEPT BioRobotics worth $24,607,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Rhumbline Advisers grew its holdings in PROCEPT BioRobotics by 5.6% in the 4th quarter. Rhumbline Advisers now owns 61,296 shares of the company's stock worth $4,936,000 after buying an additional 3,242 shares in the last quarter. Americana Partners LLC boosted its position in PROCEPT BioRobotics by 26.1% during the 4th quarter. Americana Partners LLC now owns 23,525 shares of the company's stock worth $1,894,000 after acquiring an additional 4,875 shares during the period. Principal Financial Group Inc. grew its stake in shares of PROCEPT BioRobotics by 137.1% in the fourth quarter. Principal Financial Group Inc. now owns 162,713 shares of the company's stock worth $13,102,000 after purchasing an additional 94,096 shares in the last quarter. New York State Common Retirement Fund increased its holdings in shares of PROCEPT BioRobotics by 30.6% during the fourth quarter. New York State Common Retirement Fund now owns 189,154 shares of the company's stock valued at $15,231,000 after purchasing an additional 44,324 shares during the period. Finally, Hussman Strategic Advisors Inc. acquired a new position in shares of PROCEPT BioRobotics during the fourth quarter valued at $1,353,000. Institutional investors and hedge funds own 89.46% of the company's stock.

Analyst Ratings Changes

PRCT has been the topic of several research analyst reports. Bank of America lowered their target price on shares of PROCEPT BioRobotics from $104.00 to $84.00 and set a "buy" rating on the stock in a research note on Friday, April 25th. Truist Financial dropped their target price on PROCEPT BioRobotics from $90.00 to $70.00 and set a "buy" rating on the stock in a report on Friday, April 11th. Wall Street Zen raised PROCEPT BioRobotics from a "sell" rating to a "hold" rating in a research note on Saturday, May 24th. Finally, Morgan Stanley lowered their price target on PROCEPT BioRobotics from $105.00 to $95.00 and set an "overweight" rating on the stock in a research report on Wednesday, February 26th. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $90.00.

Insiders Place Their Bets

In other news, Director Antal Rohit Desai sold 25,000 shares of the stock in a transaction on Thursday, June 5th. The stock was sold at an average price of $64.79, for a total value of $1,619,750.00. Following the completion of the sale, the director now owns 89,363 shares in the company, valued at $5,789,828.77. This represents a 21.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In the last quarter, insiders have sold 100,000 shares of company stock worth $6,271,250. Company insiders own 6.60% of the company's stock.

PROCEPT BioRobotics Price Performance

PRCT stock traded up $0.56 on Friday, hitting $60.22. 539,436 shares of the company's stock traded hands, compared to its average volume of 838,589. The stock has a market cap of $3.33 billion, a price-to-earnings ratio of -35.42 and a beta of 1.10. PROCEPT BioRobotics Corporation has a 1-year low of $47.04 and a 1-year high of $103.81. The company has a current ratio of 8.95, a quick ratio of 7.75 and a debt-to-equity ratio of 0.13. The stock has a fifty day moving average of $56.82 and a 200-day moving average of $66.30.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last announced its quarterly earnings data on Thursday, April 24th. The company reported ($0.45) EPS for the quarter, beating analysts' consensus estimates of ($0.49) by $0.04. The company had revenue of $69.16 million during the quarter, compared to the consensus estimate of $65.39 million. PROCEPT BioRobotics had a negative return on equity of 28.09% and a negative net margin of 36.20%. The company's quarterly revenue was up 55.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.51) EPS. On average, analysts forecast that PROCEPT BioRobotics Corporation will post -1.75 EPS for the current fiscal year.

PROCEPT BioRobotics Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).